Oncology
On the benefits of earlier oncological intervention, with Jo...
As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Patients
TMS works. Why do fewer than 1% of eligible patients get it?
A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.
Digital
Reducing the risk of at-home chemo complications with remote...
Remote patient monitoring (RPM) of vitals takes away the uncertainty of leaving symptom detection to patients.
R&D
Navigating geopolitical risks: Practical and legal mitigatio...
Geopolitical risk is now front of mind for many pharmaceutical leaders.
Oncology
Sponsored
Global oncology innovation from Hengrui Pharma
Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
